Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Tango Therapeutics (TNGX) Return on Sales (2021 - 2025)

Historic Return on Sales for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to 0.3%.

  • Tango Therapeutics' Return on Sales rose 28100.0% to 0.3% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.51%, marking a year-over-year increase of 13300.0%. This contributed to the annual value of 3.1% for FY2024, which is 3100.0% down from last year.
  • Latest data reveals that Tango Therapeutics reported Return on Sales of 0.3% as of Q3 2025, which was up 28100.0% from 12.21% recorded in Q2 2025.
  • Tango Therapeutics' Return on Sales' 5-year high stood at 0.3% during Q3 2025, with a 5-year trough of 12.21% in Q2 2025.
  • Moreover, its 5-year median value for Return on Sales was 4.2% (2022), whereas its average is 4.13%.
  • Its Return on Sales has fluctuated over the past 5 years, first soared by 28900bps in 2023, then tumbled by -109300bps in 2025.
  • Over the past 5 years, Tango Therapeutics' Return on Sales (Quarter) stood at 3.86% in 2021, then decreased by -18bps to 4.54% in 2022, then dropped by -25bps to 5.66% in 2023, then tumbled by -61bps to 9.14% in 2024, then surged by 103bps to 0.3% in 2025.
  • Its last three reported values are 0.3% in Q3 2025, 12.21% for Q2 2025, and 7.4% during Q1 2025.